AbbVie (ABBV) Cash from Investing Activities (2012 - 2026)

AbbVie (ABBV) has 15 years of Cash from Investing Activities data on file, last reported at -$574.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$574.0 million, up 21.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.5 billion (up 45.83% YoY), and the FY2025 annual result was -$6.6 billion, up 68.09% from the prior year.
• Cash from Investing Activities climbed to -$574.0 million in Q1 2026 per ABBV's latest filing, from -$1.5 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $1.3 billion in Q3 2022 and troughed at -$9.6 billion in Q1 2024.
• A 5-year average of -$1.8 billion and a median of -$800.0 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 309.11% in 2022, then slumped 2137.4% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$448.0 million in 2022, then tumbled by 78.57% to -$800.0 million in 2023, then sank by 134.25% to -$1.9 billion in 2024, then increased by 21.93% to -$1.5 billion in 2025, then soared by 60.77% to -$574.0 million in 2026.
• Business Quant data shows ABBV's Cash from Investing Activities at -$574.0 million in Q1 2026, -$1.5 billion in Q4 2025, and -$3.3 billion in Q3 2025.